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Summary.-C3H and C57 BL/6 mice carrying methylcholanthrene-induced fibro-
sarcomas were injected i.p. daily with histamine, metiamide (anti-histamine type-2
receptor), histamine+metiamide, mepyramine (anti-histamine type-i receptor),
serotonin and methysergide (anti-serotonin). Inhibition of tumour growth and
lengthened survival were observed with histamine and histamine+metiamide. The
best results (both on tumour growth and survival) were obtained with serotonin.
Survival was increased by metiamide and decreased by mepyramine and methy-
sergide. In histamine-treated and in serotonin-treated mice, histological studies of
the tumours showed large and numerous foci of haemorrhagic necrosis.
Stimulation of histamine type-I or serotonin receptors and inhibition of histamine
type-2 receptors play a beneficial role in the host's defence against tumours.
WE HAVE recently shown that, in mice
and rats, the presence of a growing
tumour caused increased histamine levels
in tissues, even those distant from the
tumour. These data were obtained in C3H
and C57BL/6 mice bearing a methyl-
cholanthrene-induced fibrosarcoma, in
Wag rats bearing an aflatoxin B1-induced
hepatoma and in Commentry rats bearing
a graft hepatoma (Scheinmann et al., 1979;
Burtin et al., 198lb).
Despite that increase, the immediate
hypersensitivity reactions (passive and
active, local and general) were depressed
in C3H mice carrying a 3-methyleholan-
threne induced fibrosarcoma (McC3-1)
(Lynch & Salomon, 1977a). These data
suggested that the tumour induced a
deficit in histamine availability which
might favour its growth. Indeed, when
this deficit was overcome, the tumour
growth was inhibited. This inhibition was
obtained by eliciting intratumour passive
local anaphylaxis with an extremely high
IgE antibody titre, leading to the release
of vaso-active amines (Lynch & Salomon,
1977b). Furthermore, daily i.p. injections
of free histamine significantly inhibited
tumour growth in C3H and C57BL/6
mice. Histological studies have shown the
presence of numerous large loci of acute
haemorrhagic necrosis in tumours of
histamine-treated mice (Burtin et al.,
1 981c).
The aim of this work was to study
which histamine receptors and which
mechanisms were involved in this
phenomenon.
MATERIALS AND METHODS
Histamine dihydrochloride (Prolabo) and
serotonin (5-hydroxytryptamine and
creatinin sulphate, Prolabo) solutions wAere
neutralized with NaOH and contained 50 mg
of histamine 2HCl/ml and 4 mg/ml of sero-
tonin. Metiamide (S.K.F., H2-receptor antag-
onist), mepyramine (Specia, Hl-receptor
antagonist) andmethysergide (U.M.L. Sandoz,
anti-serotonin) wN-ere used in solution contain-
ing 5 mg/ml, 1 mg/ml and 250 jug/ml,
respectively. Each group of mice receivedTUMOURS TREATED WITH HISTAMINE AND SEROTONIN
0-2 mli.p. ofone ofthese solutions and control
groups were injected i.p. with 0-2 ml of
saline solution.
Tumour diameters were measured 3 x a
week. Statistical analysis used the t test.
Female C3H and male C57BL/6 (8-16
weeks old) were used throughout the experi-
ments. The colony of mice was initially
cesarean-derived and then maintained in a
barrier-protected environment.
C57BL/6 bearing the MIcB6-1 fibrosar-
coma.-Fibrosarcomas, originally induced by
s.c. injection of 2 mg MCA in female
C57BL/6 mice and serially transplanted in
syngeneic males or females, were used
between the 15th and the 25th passages.
Tumours were removed aseptically and cut
into small pieces which were then stirred
in 0.25% trypsin (Difco) in phosphate
buffered saline for 90 min at 37°C. The
immunogenicity of the McB6-1 tumour was
previously demonstrated (Poupon et al.,
1979).
Sixty C57BL/6 male mice each received
s.c. 104 tumour cells. One day after the cell
transfer, mice were randomly divided into 6
equal groups. Each group was injected i.p.
7 days/week with saline solution, histamine
base (6 mg), metiamide (1 mg), histamine base
(6 mg)+metiamide (1 mg), mepyramine (0-2
mg) and serotonin (0-8 mg).
C3H mice bearing the McC3-1 fibrosar-
coma.-Fibrosarcomas induced in C3H mice
by the i.m. injection of 1 mg 3-methylcho-
lanthrene were maintained by serial trans-
plantation in syngeneic mice and freezing of
various passages. The McC3 fibrosarcoma was
used between the 15th and 25th passages.
Tumour grafts were performed ventrally
by the s.c. introduction of small pieces
(,< 1 mm3) of non-necrotic tumour via a
trocar needle. This tumour was immuno-
genic as described by Lynch et al. (1978).
Three different experiments were per-
formed (mice were injected i.p. 5 days/week).
Five days after the tumour cell transfer,
(1) 10 mice received histamine (6 mg) and
10 mice saline solution and (2) 14 mice
received serotonin (0-8 mg) and 10 mice
saline solution. In the third experiment, 3
groups of 12 mice received serotonin (0.8),
methysergide (50 jg) or saline solution 20
days after the tumour-cell transfer.
Three serotonin-treated and 3 control C3H
miceinjectedas describedinthesecondexperi-
ment, were killed at Day 20 after the tumour-
cell transfer. Tumour fragments were fixed
in Bouin's fluid, embedded in paraffin, and
stained with haematoxylin and eosin.
RESULTS
Histamine treatment in C3H mice
Histamine significantly inhibited tum-
our growth for at least 68 days and
increased survival (Table I).
Histamine andanti-histamines (anti-Hi and
anti-H2) treatment in C57BL/6 mice
Histamine alone significantly inhibited
tumour growth for 30 days and increased
survival (Table II and Fig. 1). Metiamide
alone had no effect on tumour growth, but
significantly increased survival (Table II
and Fig. 2).
Treatment with histamine and meti-
amide gave better results than histamine
alone for inhibition of tumour growth,
but survival was not significantly different
(Table II and Fig. 2).
Mepyramine treatment induced a slight
but not significant increase in tumour
growth and a significant decrease in
survival (Table II and Fig. 1).
TABLE I.-Effect of histamine i.p. on tumour mean diameter (mm +s.d.) and survival in
groups of 10 McC3-1 C3H mice
Injection of tumour cells
Injection of histamine
* P < 0-01 by comparison with control mice (t test).
Day
0
5
12
23
37
50
68
80
Control
+
4-72+0-26
8-17+0 68
16-78+0-51
26-44+ 1 60
all dead
Histamine
+
4-13+0 30
6.00+0.93*
10-44+ 1.19*
15-14+ 1-71*
20-30+2-73
30-67+0-60
(4 survivors)
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TABLE IJ.-Evolution of mean tumour diameter (mm + s.d.) in McB6-1-C57BL/6 mice
Day Control
15t +
20 4-2+0-8
25 7-9+1-1
30 12-5+2 7
35 15-7+2-7
40 20-3+2-8
45' 25 3+2-7
50 29 9+2-4
Histamine Metiamide
2-9+0-4*
6-0+0-6*
8-6+ 1.4*
12-1+2-1
19-4+4-3
23-5 + 3-3
26 - 6 + 3 - 6
4-7+1 9
8-8+ 1 -3
12-3+2 0
15-1+3-4
22 9+ 3-8
26-8+4-9
30 4+5-3
Histamine and
Metiamide
2-9+ 1-0*
3.0+1-5*
8-1+1.8*
10-6+2 0*
15-7+2-3*
19-6+2.4*
24-3+2-8*
Tumour cells were injected at Day 0. At Day 1 each group of 10 mice were injected
i.p. daily.
* P < 0.05 by comparison with control mice (t test).
t Tumour palpable (+) or not (-).
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FIG. 1.-Survival curves of McB6-1 C57BL/6
mice. Day 0: injection of tumour cells. Day
1: beginning of i.p. injections of saline
solution, - ; histamine, ---; mepyr-
amine,
Serotonin and anti-serotonin treatment of
C57BL/6 and C3H mice
C57BL/6 mice. Serotonin induced a sig-
nificant decrease in tumour growth for 40
days and an increase in survival. At the
end of treatment (Day 50), 4 controls and
9 serotonin treated mice survived. At Day
60, allthe controls were deadand 5 treated
mice survived (Table III).
C3H mice treated 5 days after tumour-
cell transfer.
Tumours grew in all the control mice.
The study of serotonin-treated mice
revealed 2 distinct populations. In 7
mice, serotonin induced a significant
0 1 5 6 7 8 9 10 11 12 weeks
Fra. 2.-Survival curves of McB6-1 C57BL/6
mice. Day 0: injection of tumour cells.
Day 1: beginning of i.p. injections of saline
solution, ; metiamide, -; histamine
+metiamide, ---.
decrease in tumour growth until Day 45
(Table III). In 6 mice, the tumour never
developed, and these mice were still alive
4 months after the end of the treatment.
In one mouse, the tumour begantodevelop
at Day 16, reached a diameter of 11 mm
at Day 25, completely disappeared from
Day 44 to Day 70, and grew again in spite
ofthe treatment. Survival wassignificantly
increased (Fig. 3).
C3H mice treated 20 days after tumour-
cell transfer.
In serotonin-treated mice, inhibition of
tumour growth first appeared 15 days
after the beginning of the treatment. This
inhibition was still significant (P < 0.05)
at the end of the treatment (Day 70 after
Mepyramine
+
4-6+ 1-7
9 5+1-5
15 0+ 3-2
18-8+3-1TUMOURS TREATED WITH HISTAMINE AND SEROTONIN
TABLE III.-Evolution of mean tumour diameter (mm+s.d.) in McB6-1 C57BL/6 mice
(tumour cells injected at day 0 and serotonin begun at Day 1) and in McC3-1 C3H mice
(tumour cells injected at day 0 and serotonin begun at Day 5)
C57BL/6
Control Serotonin
Day (n= 10) (n= 10)
15
20
25
30
35
40
45
50
4-2+0-8
7-9+ 1.1
12-5+2-7
15-7 + 2-7
20-3+2-8
25-3+2-7
29 - 9 + 2 -4
2-5+0-9**
3-8+ 1.2**
8-1 + 2.3**
11 *6+3-0**
15-7+3-4*
19*8+ 6 -7*
25 -5 + 7 - 7
C3H
Control Serotonin
(n=10) (n= 14)t
5-6+1-1
8-3+1.1
10.1 + -8
11
- 8 + 2 -1
14-8 + 3-0
16-5+3-0
18 -4+ 2 -8
19-8 + 2-7
4-6+ 1-3
6-4+ 16*
8-1 + 1.5*
9-1+ 15*
11*4+ 12*
13 3+2-0*
15-3+2-1*
18 -0+ 2 - 2
t Means of 7 tumours, in the other 7 mice, tumourgrowth was
absent or transient (see text).
*P<0.05.
** P < 0-01 by comparison with control mice (t test).
the tumour-cell transfer) and all 12 mice
survived.
In methysergide-treated mice, a slight
but non-significant increase in tumour
growth was observed. However, as in
mepyramine-treated mice, the survival
decreased: at Day 70, only 25% sur-
vived, while in control mice 66% sur-
vived.
presence of bands and foci of necrotic and
haemorrhagic tissue. These lesions were
observed in the central part of tumours
(Fig. 5) as well as at the periphery (Fig. 6).
This resembled acute necrosis, associated
or not with a haemorrhagic phenomenon.
No cellular infiltrates surrounded the
necrotic areas.
Histology
Histological examination showed the
fibroscarcoma type ofthe tumour (Fig. 4).
C3H mice treated with serotonin had a
modified histological structure of the
tumours. This consisted mostly of the
% survival
100 . *
90
80
70
60
50
40
30
20
10
0 .6
P 0.01
4**_
weeks
FIG. 4.-Typical histological picture of a
McC3-1 fibrosarcoma in a C3H mouse.
H. & E. Original magnification. x 150.
FIG. 3.-Survival curves ofMcC3-1 C3H mice.
Day 0: injection of tumour cells. Day 5:
beginning of i.p. injections of saline solu-
tion, ; serotonin, -
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FIG. 5. McC3-1 fibrosarcoma in a serotonin-
treated C3H mouse. H. & E. Original magni-
fication x 150. Lesions in the central part
ofthe tumour.
FIG. 6. McC3-1 fibrosarcoma in a serotonin-
treated C3H mouse. H & E. Original magni-
fication x 150. Lesions in the periphery of
the tumour.
DISCUSSION
Our results confirm the inhibition by
i.p. injections of histamine of tumour
growth in C3H and C57BL/6 mice bear-
ing methylcholanthrene-induced fibro-
sarcomas (Burtin et al., 1981c). Histamine
also lengthened the survival of tumour-
bearing mice.
The analysis of the histamine receptors
involved was performed with histamine-
receptor antagonists. I.p. injections of
metiamide, a histamine type 2-receptor
antagonist did not influence tumour
growth, but significantly lengthened the
survival oftumour-bearing C57BL/6 mice.
Longer survival has also been found with
oral cimetidine (another histamine type 2-
receptor antagonist) in C57BL/6 mice
injected with 3 LL tumour cells (Osband
et al., 1981) and in the C57BL/6-EL4 and
C3H-Mc43 tumour models (Gifford et al.,
1981). The inhibiting effect of cimetidine
on tumour growth was attributed to the
inhibition of suppressor cells. In our
experiments, the simultaneous use of
histamine and metiamide gave better
results than either histamine or metiamide
alone on tumour growth (Burtin et al.,
1981a). Since histamine has been shown
to exertanimmuno-inhibitoryrolethrough
the stimulation of the type-2 receptors on
T lymphocytes (Plaut et al., 1973; Rocklin
et al., 1980) the beneficial effects of hist-
amine alone should be attributed to the
stimulation ofthe histamine type-I recep-
tors. This fact was confirmed by the
increased mortality during treatment with
mepyramine (a histamine type 1-receptor
antagonist) treatment. Mepyramine prob-
ably favoured tumour growth by adding
its pharmacological effects (decrease of
vascular permeability) to the decrease in
histamine availability induced by the
tumour itself. Indeed, Lynch & Salomon
(1977b) have shown that the i.v. injection
of a McC3-1 acellular extract in normal
mice inhibited the passive cutaneous
anaphylaxis reactions. This experiment
suggested an "antihistaminic" activity
by the tumour. Mepyramine increased this
antihistaminic action and thus decreasedTUMOURS TREATED WITH HISTAMINE AND SEROTONIN 59
the host's defence against the tumour.
Conversely, the stimulation of the hist-
amine type 1 receptor induced an increase
in vascular permeability which probably
assisted the intratumoral penetration of
host immune antitumour elements
(Askenase, 1977; Lynch & Salomon,
1977b). It has been previously shown that
the McC3-1 and McB6-1 tumours induced
immune antitumour reactions mediated
by a thymus-derived lymphocyte (Poupon
et at., 1979; Lynch et al., 1978).
The essential role of increased vascular
permeability in this defence was con-
firmed by the results of serotonin treat-
ment. This amine, the most important
factor for increasing vascular permeability
in mice (Schwartz et al., 1977) induced the
longest survival and the strongest tumour
inhibition. This antitumour effect of
serotonin operated even when treatment
was begun in mice bearing large tumours
(diameter 8-10 mm). Contrary to the
double and opposite action of histamine,
serotonin activity seems to be dependent
on a single mechanism. Indeed, serotonin
has no demonstrable effect on mouse
lymphocytes (Schwartz et al., 1977).
Finally,* the increase in tumour growth
induced by anti-serotonin treatment prob-
ably involved mechanisms similar to
mepyramine on vascular permeability.
The histological findings in serotonin-
treated mice were similar to those in
histamine-treated mice (Burtin et al.,
1981c) and argue in favour of the same
vascular participation.
Histamine and serotonin treatments
were more active in C3H mice than in
C57BL/6 mice. Further experiments will
determine whether it is the strain or the
tumour which accounts for the difference.
The vascular effects of vasoactive
amines are perhaps insufficient to explain
their antitumoral effects. In vitro experi-
ments in guinea-pig cells (Dvorak et al.,
1979) have shown that attachment of
membrane free extruded basophil gran-
ules to their cell surfaces killed tumour
cells. Furthermore, in microcytotoxicity
assays in vitro, peritoneal mouse mast
cells were found to be cytotoxic to cells
of a mouse methylcholanthrene induced
fibrosarcoma. None of the antihistaminics
(both anti-Hi and anti-H2) caused any
reduction in cytotoxicity. In contrast,
reserpine blocked tumour killing, sug-
gesting serotonin as the principal agent
of tumour-cell killing in mice (Farram
et al., 1980). Furthermore, the endogenous
peroxidase activity of peritoneal mast-
cell granules has been shown in vitro to be
toxic to mammalian tumour cells, when
combined with H202 and iodide (Hender-
son etal., 1981).
Whatever the mechanism(s), our experi-
mentsintumour-bearing micehavedemon-
strated that stimulation of histamine
type-I or serotonin receptors and inhibi-
tion of histamine type-2 receptor play a
beneficial role in the host's defence against
tumours.
We thank Dr C. R. Ganellin (S.K.F.) for a gift of
metiamide used in this study and Mrs Ch. Faure
and R. Merda for their technical assistance.
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